Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
Previous Symbol
CUSIP62855J10
Phone801-584-3600
Debt
Debt-to-Equity Ratio0.23
Current Ratio3.17
Quick Ratio2.83
Price-To-Earnings
Trailing P/E Ratio26.18
Forward P/E Ratio20.94
P/E Growth1.82
Sales & Book Value
Annual Sales$772.60 million
Price / Sales3.04
Cash Flow$1.9830 per share
Price / Cash15.84
Book Value$14.74 per share
Price / Book2.13
Profitability
EPS (Most Recent Fiscal Year)$1.20
Net Income$131.10 million
Net Margins7.07%
Return on Equity10.07%
Return on Assets7.62%
Miscellaneous
Employees2,400
Outstanding Shares74,760,000
Market Cap$2.35 billion
OptionableOptionable
Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
How were Myriad Genetics' earnings last quarter?
Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday, November, 6th. The company reported $0.43 EPS for the quarter, beating the Zacks' consensus estimate of $0.30 by $0.13. The company earned $202.30 million during the quarter, compared to analyst estimates of $203.20 million. Myriad Genetics had a net margin of 7.07% and a return on equity of 10.07%. The firm's revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 EPS. View Myriad Genetics' Earnings History.
When is Myriad Genetics' next earnings date?
What guidance has Myriad Genetics issued on next quarter's earnings?
Myriad Genetics issued an update on its FY19 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.74. The company issued revenue guidance of $855-865 million, compared to the consensus revenue estimate of $895.07 million.Myriad Genetics also updated its FY 2019 guidance to $1.70-1.75 EPS.
What price target have analysts set for MYGN?
9 equities research analysts have issued 12 month target prices for Myriad Genetics' shares. Their forecasts range from $25.00 to $54.00. On average, they anticipate Myriad Genetics' share price to reach $41.1111 in the next year. This suggests a possible upside of 30.9% from the stock's current price. View Analyst Price Targets for Myriad Genetics.
What is the consensus analysts' recommendation for Myriad Genetics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.
What are Wall Street analysts saying about Myriad Genetics stock?
Here are some recent quotes from research analysts about Myriad Genetics stock:
- 1. According to Zacks Investment Research, "Over the past three months, Myriad Genetics has outperformed its industry. The company observed strong growth in GeneSight, Vectra DA, EndoPredict and Prolaris testing revenues, in the last reported quarter. Further, management believes that Hereditary cancer pricing has remained stable on a sequential basis for three consecutive quarters. We are upbeat about Myriad Genetics’ expectation to witness a stable pricing trend throughout fiscal 2019. Moreover, the company seems to be positioned to deliver strong fiscal 2019 results on solid performance by new products, the recent Counsyl buyout, success of the Elevate 2020 program along with higher reimbursements for tests. However, the decline in Hereditary cancer testing revenues due to pricing issues raises concern. Currency fluctuations and stiff competition are other major headwinds." (10/29/2018)
- 2. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)
Has Myriad Genetics been receiving favorable news coverage?
Media stories about MYGN stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myriad Genetics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Are investors shorting Myriad Genetics?
Myriad Genetics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 11,793,819 shares, an increase of 19.1% from the October 15th total of 9,903,694 shares. Based on an average daily trading volume, of 747,055 shares, the days-to-cover ratio is currently 15.8 days. Approximately 17.1% of the company's stock are short sold. View Myriad Genetics' Current Options Chain.
Who are some of Myriad Genetics' key competitors?
Some companies that are related to Myriad Genetics include Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML), Riot Blockchain (RIOT) and Akers Biosciences (AKER).
Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the folowing people:
- Mr. Mark Christopher Capone, CEO, Pres & Director (Age 56)
- Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 47)
- Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 59)
- Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Alexander Ford, Pres of Myriad Women's Health (Age 51)
Who are Myriad Genetics' major shareholders?
Myriad Genetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.35%), Baillie Gifford & Co. (12.77%), Dimensional Fund Advisors LP (3.53%), Frontier Capital Management Co. LLC (3.45%), Acadian Asset Management LLC (3.19%) and Thrivent Financial for Lutherans (3.17%). Company insiders that own Myriad Genetics stock include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.
Which institutional investors are selling Myriad Genetics stock?
MYGN stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Allianz Asset Management GmbH, Dimensional Fund Advisors LP, Point72 Asset Management L.P., Wells Fargo & Company MN, S&T Bank PA, Pinnacle Associates Ltd. and Piedmont Investment Advisors Inc.. Company insiders that have sold Myriad Genetics company stock in the last year include Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.
Which institutional investors are buying Myriad Genetics stock?
MYGN stock was acquired by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, BlackRock Inc., Prudential Financial Inc., Robeco Institutional Asset Management B.V., Frontier Capital Management Co. LLC, FMR LLC, Credit Suisse AG and Baillie Gifford & Co.. View Insider Buying and Selling for Myriad Genetics.
How do I buy shares of Myriad Genetics?
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myriad Genetics' stock price today?
One share of MYGN stock can currently be purchased for approximately $31.41.
How big of a company is Myriad Genetics?
Myriad Genetics has a market capitalization of $2.35 billion and generates $772.60 million in revenue each year. The company earns $131.10 million in net income (profit) each year or $1.20 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.
What is Myriad Genetics' official website?
How can I contact Myriad Genetics?
Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]
MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
